Tremelimumab/Durvalumab Produces Favorable OS Benefit in Unresectable HCC Irrespective of ALBI Grade
June 30th 2022A single priming dose of tremelimumab added to regular interval durvalumab generated significantly improved overall survival compared with sorafenib in the frontline setting for patients with unresectable hepatocellular carcinoma, irrespective of of their baseline albumin-bilirubin grade, according to updated data from the phase 3 HIMALAYA trial.
Read More
Wenham Discusses the Growing Treatment Landscape Across Gynecologic Cancers
June 24th 2022Robert Wenham, MD, MS, FACOG, FACS, discusses the current treatment landscape for patients with cervical and endometrial cancers, ADCs and PARP inhibitors in ovarian cancer, advancements in HER2-positive breast cancer, and surgical options for patients with ovarian cancer.
Read More
Talquetamab Monotherapy Shows Early Promise in Relapsed/Refractory Multiple Myeloma
June 22nd 2022Monique Minnema, MD, discusses the rationale of the MonumenTAL-1 trial examining talquetamab in multiple myeloma, the safety and efficacy reported thus far with the bispecific antibody, and next steps for further exploration.
Read More
Guadecitabine Fails to Improve OS Over Physician’s Choice of Treatment in MDS and CMML
June 21st 2022Guadecitabine did not result in a statistically significant improvement in overall survival compared with physician’s choice of treatment in patients with relapsed/refractory myelodysplastic syndrome or chronic myelomonocytic leukemia, according to data from the phase 3 ASTRAL-3 trial.
Read More
Trastuzumab Deruxtecan Elicits Statistically Significant PFS in HR-Positive/HER2-Low Breast Cancer
June 20th 2022Fam-trastuzumab deruxtecan-nxki demonstrated a statistically significant benefit in progression-free survival in patients with HER2-low metastatic breast cancer, meeting the primary end point of the phase 3 DESTINY-Breast04 trial and changing the standard of care for this patient population.
Read More
Quavonlimab/Pembrolizumab Combo Shows Modest Antitumor Activity in Advanced Melanoma
June 16th 2022The combination of quavonlimab and pembrolizumab was found to be generally well tolerated and to have modest antitumor activity in patients with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor, according to data from a phase 1/2 trial (NCT03179436).
Read More
Zanubrutinib Improves QOL Outcomes Vs Bendamustine/Rituximab in CLL/SLL
June 13th 2022Zanubrutinib achieved favorable health-related quality of life outcomes compared with bendamustine plus rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma.
Read More
Neoadjuvant Enfortumab Vedotin May Be an Option for Cisplatin-Ineligible MIBC
May 28th 2022Neoadjuvant administration of the antibody drug conjugate enfortumab vedotin-ejfv represents a potential future treatment option for patients with muscle invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Read More
Fox Chase Cancer Center Experts Highlight the Growing Treatment Landscapes in Lung Cancer
May 27th 2022Multiple FDA-approved frontline immunotherapy options have continued to shape the treatment paradigm in non–small cell lung cancer. Additionally, more knowledge regarding the effects of immunotherapy on certain driver mutations has helped drive therapy decisions across lines of treatment.
Read More
Frontline Encorafenib/Cetuximab Plus or Minus Chemo Is Under Evaluation for BRAF V600E–Mutant mCRC
May 25th 2022The safety and efficacy of encorafenib plus cetuximab with or without standard-of-care chemotherapy will be compared with that of chemotherapy alone in patients with BRAF V600E–mutated metastatic colorectal cancer as part of the phase 3 BREAKWATER trial.
Read More
Biomarker Testing Is A Critical Component in Treatment of Gynecologic Cancers
May 25th 2022Rebecca A. Previs, MD, discusses the role of biomarkers in uterine and endometrial cancers, the standard of care for patients with different biomarkers in uterine cancer, how PARP inhibitors have affected the treatment of ovarian cancer, and the key clinical trials in gynecologic cancers.
Read More
Emerging Chemotherapy-Free Approaches Raise Sequencing Questions in MCL Management
May 24th 2022Martin F. Dietrich, MD, PhD, highlights recent updates in mantle cell lymphoma treatment, explains how new developments have raised sequencing questions, and projects where future research efforts will focus.
Read More
Monk Breaks Down Recent Advances Across the Gynecologic Cancer Paradigm
May 22nd 2022Bradley J. Monk, MD, FACS, FACOG, discusses the future of ovarian cancer treatment, ongoing and future trials, as well as combination therapies that may benefit patients with ovarian cancer, cervical cancer, and endometrial cancer.
Read More
Sacituzumab Govitecan Under Further Exploration in Metastatic Urothelial Cancer
May 19th 2022Sacituzumab govitecan will be further evaluated in patients with locally advanced unresectable or metastatic urothelial cancer that has progressed after prior platinum or checkpoint inhibitor therapy, as a part of the phase 3 TROPiCS-04 trial.
Read More
Sabizabulin Yields Encouraging rPFS, Tolerable Toxicity Profile in Previously Treated mCRPC
May 17th 2022The utilization of sabizabulin in patients with metastatic castration-resistant prostate cancer who progressed on androgen receptor-targeting therapy yielded significant and durable objective tumor responses, according to results of a phase 1b/2 trial (NCT03752099).
Read More
Stanford Faculty Break Down Advancements in Women’s Cancer Care
May 13th 2022Advancements in treatment options across the spectrum on women’s cancers include de-escalating therapy in HER2-positive breast cancer, using tisotumab vedotin-tftv in cervical cancer, shifting therapies to the frontline setting in endometrial cancer, and using checkpoint inhibitors in ovarian cancer.
Read More
Emerging Targeted Therapies Continue to Shift Paradigm in EGFR Exon 20–Mutated NSCLC
May 12th 2022Edward Kim, MD, MBA, discussed the facets of each presentation from the meeting, featuring other emerging targeted therapies in NSCLC, biomarker testing in the space, frontline immunotherapy in NSCLC, and the current management of small cell lung cancer.
Read More
Pilot Study Shows Promising Results With CPX-351 in Relapsed/Refractory ALL
May 12th 2022Bijal Shah, MD, MS, discusses the results of a phase 2 pilot study investigating CPX-351 in adults with high-risk relapsed/refractory acute lymphoblastic leukemia, as well as next steps for research in this patient population.
Read More
Vibostolimab/Pembrolizumab Combo Elicits Antitumor Activity in Metastatic Cervical Cancer
May 11th 2022Two investigated doses of vibostolimab in combination with pembrolizumab resulted in comparable antitumor activity and safety in patients with locally advanced or metastatic cervical cancer who were naïve to PD-1/PD-L1 inhibitors, regardless of PD-L1 status.
Read More
Nihilism Remains a Barrier to Effective Treatment Delivery in Pancreatic Cancer
May 10th 2022Jonathan Mizrahi, MD, discusses updates from the meeting in pancreatic cancer and hepatocellular carcinoma, the growing role of immunotherapy in GI cancer, and the ‘watch and wait’ protocol seen in rectal cancer
Read More